Klingenstein Fields & Co. LLC Has $525,000 Stake in Novo Nordisk A/S (NVO)

Klingenstein Fields & Co. LLC Has $525,000 Stake in Novo Nordisk A/S (NVO)

Klingenstein Fields & Co. LLC continued to hold its position in shares of Novo Nordisk A/S (NYSE:NVO) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,625 shares of the company’s stock at the end of the third quarter. Klingenstein Fields & Co. LLC’s holdings in Novo Nordisk A/S were worth $525,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of NVO. Investment Centers of America Inc. increased its position in shares of Novo Nordisk A/S by 0.4% in the second quarter. Investment Centers of America Inc. now owns 6,713 shares of the company’s stock valued at $363,000 after buying an additional 28 shares during the last quarter. Bremer Trust National Association increased its position in shares of Novo Nordisk A/S by 0.5% in the third quarter. Bremer Trust National Association now owns 7,928 shares of the company’s stock valued at $330,000 after buying an additional 36 shares during the last quarter. Redmond Asset Management LLC increased its position in shares of Novo Nordisk A/S by 0.3% in the second quarter. Redmond Asset Management LLC now owns 16,044 shares of the company’s stock valued at $863,000 after buying an additional 44 shares during the last quarter. Financial Architects Inc increased its position in shares of Novo Nordisk A/S by 0.8% in the third quarter. Financial Architects Inc now owns 7,009 shares of the company’s stock valued at $291,000 after buying an additional 55 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. increased its position in shares of Novo Nordisk A/S by 0.3% in the third quarter. Neville Rodie & Shaw Inc. now owns 19,725 shares of the company’s stock valued at $820,000 after buying an additional 56 shares during the last quarter. Hedge funds and other institutional investors own 7.32% of the company’s stock.

Shares of Novo Nordisk A/S (NYSE:NVO) opened at 35.78 on Friday. The company’s 50 day moving average price is $35.71 and its 200-day moving average price is $41.55. Novo Nordisk A/S has a 52 week low of $30.89 and a 52 week high of $57.81. The firm has a market capitalization of $90.40 billion, a PE ratio of 16.97 and a beta of 0.82.

A number of equities research analysts have recently weighed in on the company. Jefferies Group LLC restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 20th. Bank of America Corporation downgraded Novo Nordisk A/S from a “neutral” rating to an “underperform” rating in a research report on Friday, October 28th. J P Morgan Chase & Co downgraded Novo Nordisk A/S from a “neutral” rating to an “underweight” rating in a research report on Tuesday, January 3rd. DNB Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, October 31st. Finally, Zacks Investment Research downgraded Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Monday, November 14th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the stock. Novo Nordisk A/S has an average rating of “Hold” and an average target price of $60.00.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).

Related posts

Leave a Comment